Percutaneous Nephrolithotomy (PCNL) System Market Fueled by Single-Use Tech

Percutaneous Nephrolithotomy (PCNL) System Market Size, Key Players with Insights

The global percutaneous nephrolithotomy (PCNL) system market size is calculated at US$ 1.34 billion in 2024, grew to US$ 1.44 billion in 2025, and is projected to reach around US$ 2.7 billion by 2034. The market is expanding at a CAGR of 7.25% between 2025 and 2034.

Across the world, many medical device manufacturers are fostering the broader developments of single-use or disposable product types in effective surgical procedures. The percutaneous nephrolithotomy (PCNL) system market is exploring several advancements in laser technology, mini-PCNL/miniaturized PCNL, as well as growth in urology surgical infrastructure (especially in hospitals and ambulatory surgical centers), which is also bolstering the overall market development.

Key Takeaways

• Percutaneous nephrolithotomy (PCNL) system market to crossed USD 1.34 billion by 2024.
• Market projected at USD 2.7 billion by 2034.
• CAGR of 7.25% expected in between 2025 to 2034.
• North America dominated the market with 38% revenue share in 2024.
• Asia Pacific is expected to be the fastest-growing region in the studied years.
• By product/system component, the nephroscopes & endoscopes segment led with 25% share of the market in 2024.
• By product/system component, the lithotripsy generators & probes segment is expected to grow rapidly during 2025-2034.
• By procedure type/approach, the standard (conventional) PCNL segment held 40% revenue share of the percutaneous nephrolithotomy (PCNL) system market in 2024.
• By procedure type/approach, the mini-PCNL/miniaturized PCNL segment is expected to witness the fastest growth during the forecast period.
• By device type, the reusable rigid/video nephroscopes segment registered dominance with 55% share of the market in 2024.
• By device type, the single-use/disposable scopes & sheaths segment is expected to grow at a rapid CAGR in the coming years.
• By end-user/facility type, the hospitals (tertiary & general hospitals) segment held a major share of 60% of the market in 2024.
• By end-user/facility type, the ambulatory surgical centers (ASCs)/day-case units segment is expected to be the fastest-growing in the upcoming years.

Key Indicators and Highlights

How is the Percutaneous Nephrolithotomy (PCNL) System Transforming?

The percutaneous nephrolithotomy (PCNL) system market covers the range of devices, accessories, consumables, and technologies used to perform percutaneous nephrolithotomy, a minimally invasive surgical procedure to remove kidney stones via a small skin incision, tract creation into the kidney, and instrument access for fragmentation and extraction. Growth is driven by increasing incidence of kidney stone disease globally, preference for minimally invasive urological treatments, expansion of urology surgical infrastructure (especially in hospitals and ambulatory surgical centers), and continual product innovation (mini-, ultra-mini-, micro-PCNL, integrated imaging/robotics).

The systems include nephroscopes, dilators/access sheaths, lithotripters (ultrasonic, pneumatic, laser, electrohydraulic), imaging guidance modules, and ancillary kits (access guidance, suction/irrigation, stone retrieval).

Percutaneous Nephrolithotomy (PCNL) System Market Outlook:

• Global Expansion: Ongoing advancements in miniaturization and robotic integration, and expanded use of data-driven approaches, such as AI for treatment planning and outcome prediction.
• Industry Growth Overview: The market is encouraging single-use scopes and other ancillary instruments, highlighting sterilization risks, lowering cross-contamination challenges, and streamlining procedural workflows.
• Startup Ecosystem:  In September 2025, Mendaera announced the first successful PCNL procedures using Focalist after receiving FDA clearance in July 2025 for placing instruments in adult and pediatric patients.

Trends in the Percutaneous Nephrolithotomy (PCNL) System Market

• In August 2025, HealthTronics, LLC, a significant provider of kidney stone management solutions to urologists, health systems, and patients, successfully recapitalized the company and received a new equity investment from Secretariat Capital.
• In June 2025, at the 2025 American Urological Association Annual Meeting, the Monarch Platform facilitated extended capabilities for robot-assisted mini-PCNL, as it is safe and efficient in the treatment of nephrolithiasis.

What are the Diverse Technological Advances in the Market?

Around the globe, the percutaneous nephrolithotomy (PCNL) system market has been putting efforts into innovative technologies, such as automated needle targeting. This possesses X-ray coupled with AI algorithms, which accelerates automated calculation and adjustment of the needle towards the targeted calyx. Furthermore, the major leaders are exploring novel robotic systems that integrate robotic assistance with 3D modeling and real-time ultrasound guidance. This promising system helps in the reduction of manual errors and smooths the learning curve for novice surgeons.

Segmental Insights

Product/System Component

Why did the Nephroscopes & Endoscopes Segment Lead the Market in 2024?

In 2024, the nephroscopes & endoscopes segment captured a 25% share of the percutaneous nephrolithotomy (PCNL) system market. This type offers enhanced image quality, lowered cross-contamination risk, and a plug-and-play design. The market is leveraging sophisticated digital nephroscopes that are replacing conventional fiber-optic models, with wider advances in three-dimensional visualization with optimized depth perception, anatomical detail, and surgical control for complex procedures.

Lithotripsy Generators & Probes

The lithotripsy generators & probes segment will expand fastest in the coming years. Mainly, it comprises advancements with lasers, which have made PCNL a highly efficient and safer procedure. The recently developed Swiss LithoClast Trilogy is a single-probe, dual-energy device that describes a milestone step. The use of tiny, robust lithotripter probes allows the progression of mini- and micro-PCNL, which use smaller access tracts.

Access Sheaths, Dilators & Tract Kits

The access sheaths, dilators & tract kits segment will expand notably in the future. Ongoing advances are fostering smaller-diameter access sheaths (14–20 Fr), dilators, and nephroscopes are employed for mini-PCNL. The emergence of balloon dilation promotes a faster, single-step method that employs an expandable balloon catheter to dilate the tract.

Procedure Type/Approach Insights

How did the Standard (Conventional) PCNL Segment Dominate the Market in 2024?

The standard (conventional) PCNL segment led with a 40% share of the percutaneous nephrolithotomy (PCNL) system market in 2024. A rise in the geriatric population, which is more prone to kidney stones, has fueled the significant demand for this procedure. According to a study, in 2021, 106 million cases of kidney stones were found, and it is predicted to rise to $1.24 billion/yr by 2030.

Mini-PCNL/Miniaturized PCNL

The mini-PCNL/miniaturized PCNL segment will expand rapidly during 2025-2034. Current advances are bolstering variations in this approach, like mini-PCNL, ultra-mini-PCNL, micro-PCNL, and super-mini-PCNL (SMP), each with its own set of instruments and intended utilization. Alongside, the market is revolutionizing surgical tools, including smaller nephroscopes and novel laser techniques, and advanced percutaneous sheaths.

Supine PCNL vs the Prone PCNL

The supine PCNL vs the prone PCNL segment will expand significantly. The latest breakthroughs of this solution are facilitating reduced operative times, minimizing anesthetic risks, and convenient access for bilateral or simultaneous procedures. Incorporation of the Galdakao-modified Valdivia position is crucial for optimizing stone clearance.

Device Type Insights

Why did the Reusable Rigid/Video Nephroscopes Segment Dominate the Market in 2024?

By capturing a 55% share, the reusable rigid/video nephroscopes segment led the percutaneous nephrolithotomy (PCNL) system market in 2024. These types are offering their stability, durability, affordability, and feasible utility, mainly in removing large or complex kidney stones. Alongside, the video type explores superior high-definition visualization and expanded maneuverability.

Single-Use/Disposable Scopes & Sheaths

The single-use/disposable scopes & sheaths segment is predicted to register rapid expansion. This leverages a guarantee of a sterile device for every patient, diminishing reprocessing errors and connected hospital-acquired infections (HAIs). Innovative digital disposable nephroscopes facilitate a chip-on-tip design that conveys high-quality imaging without requiring separate, bulky processors and light sources.

Disposable Access Kits/Dilator Sets

The disposable access kits/dilator sets segment will expand at a lucrative CAGR. Specifically, modern kits are firm, kink-resistant guidewires and puncture needles with special tips for enhanced ultrasound visualization. Some of them encompass polytetrafluoroethylene (PTFE) coating on guidewires and dilators to lower friction.

End-User/Facility Type Insights

What Made the Hospitals (Tertiary & General Hospitals) Segment Dominant in the Market in 2024?

In 2024, the hospitals (tertiary & general hospitals) segment captured a 60% share of the percutaneous nephrolithotomy (PCNL) system market. They are increasingly investing in advanced PCNL systems, lasers, and imaging equipment to transform and boost the urological treatment. Also, they are necessary in training new urologists in PCNL techniques, to ensure a pipeline of skilled professionals.

Ambulatory Surgical Centers (ASCs)/Day-Case Units

Whereas the ambulatory surgical centers (ASCs)/day-case units segment is estimated to register the fastest growth. They offer raised safety and effectiveness, with lower expenses, and expanded patient satisfaction.  A major development includes complete or hybrid ultrasound-guided PCNL, which skips radiation exposure for both patients and staff.

Specialty Urology Clinics/Stone Centers

The speciality urology clinics/stone centers segment will expand significantly in the future. Nowadays, they are using the "totally tubeless" technique to minimize the requirement for any drainage tubes (nephrostomy tube or internal stent) in select cases. Besides this, they employ sophisticated 3D imaging, navigation systems, and mixed-reality (MR) technology to boost puncture accuracy.

Regional Insights

Why did North America Dominate the Market in 2024?

North America’s percutaneous nephrolithotomy (PCNL) system market held a 38% share in 2024. The drivers are suitable reimbursement policies, accelerated patient awareness, government funding for research, and the faster adoption of novel medical technologies. Certain centers of this region are safely executing protocols for same-day discharge in select PCNL patients. Researchers are working on laser technology, especially the thulium fiber laser and high-power holmium YAG laser.

A Surge in Transformation of Robotics Systems: US Market Trends

The U.S. is a major country in the percutaneous nephrolithotomy (PCNL) system market, including the respective one, which escalates with the broader emergence of robotics systems, which enable assistance to surgeons with needle punctures and new robotic systems assist surgeons with needle punctures and instrument manipulation for higher accuracy. Alongside, the US is widely adopting minimally invasive techniques, which boost inpatient to outpatient settings.

Combined Factors and Technological Advances are Driving the Asia Pacific

The rising cases of kidney stone disease are driven by dietary habits, sedentary lifestyles, and metabolic disorders, which support the prospective growth in the percutaneous nephrolithotomy (PCNL) system market. Alongside, ASAP is increasingly shifting towards the progression and wider adoption of advanced PCNL systems, such as miniaturized instruments, which are impacting the patient base to include pediatric and geriatric cases.

For instance,

• In August 2025, Asia Healthcare Holdings invested Rs 400 crore in the Asian Institute of Nephrology and Urology to double the hospital network. 

Stepping into mini-PCNL Advancements: China Market Trends.

The respective market in China is highly promoting the developments in the "Chinese mini-PCNL" which utilizes a tiny 14–18F percutaneous tract and an 8/9.8F rigid ureteroscope. This assists in lowering blood loss, minimizing hospital stays, and reducing postoperative pain compared to conventional PCNL, particularly for complex stones. The widespread adoption of SAS technology is refined with the double-sheath negative pressure mini-PCNL, which has shown superior immediate outcomes.

Raised Adoption of AI and ECIRS is Driving Europe

Europe is experiencing a notable expansion in the percutaneous nephrolithotomy (PCNL) system market. This region is leveraging AI-enabled algorithms in the analysis of patient data and imaging for estimating surgical success (stone-free rate) and complication risks. Moreover, the emergence of endoscopically guided access (ECIRS) is integrating flexible ureteroscopy with PCNL, which offers the detection of the optimal puncture site from within the kidney.

For instance,

• In February 2025, Ambu announced the European regulatory clearance (CE mark) for its Ambu aScope 5 Cysto HD solution to explore a single-use flexible cysto-nephroscopy solution.

Rising Demand in South America’s Urology Sector

The percutaneous nephrolithotomy (PCNL) system market in South America is growing steadily as hospitals modernize and minimally invasive procedures gain popularity. Increasing awareness of advanced kidney stone treatments and improving healthcare accessibility are fueling regional adoption across both public and private sectors.

Brazil Emerging as a Regional Growth Leader

In Brazil, PCNL system adoption is accelerating due to expanding healthcare infrastructure, skilled urologist training programs, and government support for modern surgical technologies. The shift toward less invasive kidney stone removal methods positions Brazil as a leading market in South America’s urology advancement. 

The Presence of Key Manufacturers: German Market Trends

Primarily, the Germany percutaneous nephrolithotomy (PCNL) system market possesses leading medical device manufacturers, including Karl Storz GmbH & Co. KG and Dornier MedTech GmbH, which are immensely putting efforts into global PCNL advancements with the production of cutting-edge equipment, such as mini-nephroscopes and advanced lithotripters. Also, Germany is emphasizing making the procedure robust, less invasive, and safer by adopting miniaturization, robotics, and improved imaging.

Expanded Healthcare Spending is Fueling the Middle East and Africa (MEA)

A prominent factor driving the percutaneous nephrolithotomy (PCNL) system market in MEA is a rise in healthcare expenses, which further offers advanced infrastructure modernization and energy-sector projects, especially in the Middle East. In certain countries, including Saudi Arabia are highly adopting advanced PCNL solutions, though standard approaches (prone position, fluoroscopy) remain dominant for various urologists. At the same time, Africa is bolstering needs-based international alliances and workshops that are important to boost endourology access and establish local expertise in low-resource settings.

Comparative Study on PCNL: Saudi Arabia Market Trend

In the four Saudi Arabian medical centers, it has demonstrated a comparative study was conducted to analyze the efficiency of mini-PCNL versus flexible ureteroscopy (fURSL) for treating calyceal diverticulum stones between January 2020 and June 2024. This has further displayed that mini-PCNL is highly efficacious in a specific kind of stone.

Company Landscape

Boston Scientific Corporation

Company Overview

Corporate Information

• Headquarters: Marlborough, Massachusetts, USA | Year Founded: 1979 | Ownership Type: Public company (NYSE: BSX)

History & Background

Founded to develop advanced medical devices, Boston Scientific has grown into a global med-tech leader across cardiovascular, urology, endoscopy, and other segments.

Key Milestones/Timeline

• Significant organic growth in 2024 (net sales US$16.75 billion, up ~17.6 % year-on-year)
• Early 2025: Q1 net sales US$4.66 billion, up ~20.9 % reported and ~18.2 % organic.
• Oct 2025: Q3 reported net sales US$5.065 billion, growth ~20.3 % reported.

Business Overview

• Business Segments / Divisions: Cardiovascular (largest), Endoscopy, Urology & Pelvic Health, Neuromodulation, Peripheral Interventions, etc.
• Geographic Presence: Global, with major operations in North America, Europe, Asia-Pacific, and Latin America.
• Key Offerings: A wide range of medical devices, including stents, pacemakers, electrophysiology systems, urology tools (legacy & minimally invasive), and endoscopy platforms.
• End-Use Industries Served: Hospitals, ambulatory surgical centers (ASCs), clinics across cardiovascular, urology, gastroenterology, and neurology.

Key Developments & Strategic Initiatives

• Mergers & Acquisitions: Deal announced Oct 2025 to acquire remaining equity in Nalu Medical (~US$533 million) to bolster chronic pain neurostimulation portfolio.
• Partnerships & Collaborations: Regular strategic alliances, though specific urology-endoscopy ones are less highlighted in the recent data.
• Product Launches / Innovations: Continued roll-out of devices such as the FARAPULSE™ pulsed field ablation system, and expansion in the EP segment.
• Capacity Expansions / Investments: Senior notes issuance (Euro 1.5 billion) to fund general corporate purposes and possible future acquisitions.
• Regulatory Approvals: Achieved key label expansions; also faced safety alerts from the FDA on certain cardiovascular devices.
• Distribution Channel Strategy: Global direct sales and distribution, strong presence in major markets with full-service support and via ASCs/hospitals.
• Technological Capabilities / R&D Focus: Strong R&D infrastructure, focusing on innovation in minimally invasive therapies, electrophysiology, and neurostimulation.
• Core Technologies / Patents: Proprietary platforms in cardiovascular and neuromodulation; urology devices and endoscopy platforms are also part of the portfolio, though specific PCNL system patents are less publicly detailed.
• Research & Development Infrastructure: Global R&D centers, clinical trial programs, investments in next-gen therapies.
• Innovation Focus Areas: Minimally invasive procedures, neurostimulation, expanding urology and endoscopy capabilities, leveraging category leadership.

Competitive Positioning

• Strengths & Differentiators: Broad product portfolio across multiple high-growth medical device categories; strong innovation pipeline; global scale and brand.
• Market presence & Ecosystem Role: Major med-tech company, trusted by hospitals globally; strong influence over device markets.

SWOT Analysis:

• Strengths: Diversified business, global reach, strong growth in core segments.
• Weaknesses: Exposure to regulatory/safety issues (as seen by FDA alerts); large size may hamper nimbleness.
• Opportunities: Growth in minimally invasive urology (e.g., PCNL systems), expansion in emerging markets, consolidation via acquisitions.
• Threats: Regulatory scrutiny, reimbursement pressures, competition from other med-tech firms, macroeconomic headwinds.

Recent News & Updates

Press Releases / Industry Recognitions / Awards:

• The Q1 2025 results beat expectations, adjusted EPS US$0.75 vs guidance ~US$0.66-0.68, leading to raised full-year guidance. BeyondSPX
• The FDA issued warnings on two Boston Scientific heart devices tied to injuries/deaths, affecting the brand’s cardiovascular unit. AP News
• Industry Recognitions: Not specified in the recent sources.

Olympus Corporation

Company Overview

Corporate Information

• Headquarters: Ishikawa-machi, Hachioji, Tokyo, Japan
• Year Founded: 12 October 1919 (as Takachiho Seisakusho) olympus.com.sg+1
• Ownership Type: Public company (Tokyo Stock Exchange: 7733)

History & Background

Originally an optics and precision machinery company, Olympus evolved to focus on medical systems (endoscopes, surgical/therapeutic devices), significantly restructuring by divesting camera and scientific imaging businesses. Wikipedia+1

Key Milestones / Timeline

• FY ended March 31 2025: Revenue ~¥997,332 million, operating profit up ~216 % to ¥162,462 million.
• April 2025: Appointment of Bob White as CEO effective 1 June 2025, to drive med-tech transformation.

Business Overview

• Business Segments / Divisions: Endoscopic Solutions, Therapeutic Solutions, Others (medical systems)
• Geographic Presence: Worldwide, strong presence in North America, Europe, Asia Pacific; group companies globally.
• Key Offerings: Endoscopes (diagnostic and therapeutic), urology/lithotripsy / surgical access devices, imaging equipment, single-use scopes (recent partnership).
• End-Use Industries Served: Hospitals, clinics, diagnostic and surgical centers across gastroenterology, urology (kidney stones/bladder), surgery, and ENT.

Key Developments & Strategic Initiatives

• Mergers & Acquisitions: Past acquisition of Medi-Tate (2021) to expand urology portfolio.
• Partnerships & Collaborations: September 2025: Exclusive global distribution agreement with MacroLux Medical for single-use urology scopes and access sheaths.
• Product Launches/Innovations: Integration of disposable single-use ureteroscopes and suction access sheaths.
• Capacity Expansions / Investments: Strategic shift to focus med-tech; strong investment in R&D (¥103,890 million in FY2025).
• Regulatory Approvals: Not detailed in current sources for PCNL systems specifically; corporate guidance revised due to the regulatory environment.
• Distribution Channel Strategy: Global distribution agreements, both direct and via partners; recent focus on single-use urology products, inclusive of major markets (US, Canada, Europe, Asia).
• Technological Capabilities / R&D Focus: Strong imaging and endoscopy technologies; focus moving into disposable devices and urology/lithotripsy domain; transition from cameras to full medical systems.
• Core Technologies/Patents: Proprietary endoscope optics, single-use scope designs; urology access sheaths and lithotripsy accessories.
• Research & Development Infrastructure: R&D investments over ¥100 billion, global development teams, focus on digital/robotics/AI in the next phase.
• Innovation Focus Areas: Single-use scopes for urology, minimally invasive surgical systems, smart endoscopy with AI, and expanded urology market focus.

Competitive Positioning

• Strengths & Differentiators: Long-standing leadership in endoscopy; broad presence in imaging and surgical access; expanding urology portfolio; global distribution.
• Market presence & Ecosystem Role: Key supplier to hospitals for endoscopic and surgical devices; pivotal in urology access/lithotripsy systems.

SWOT Analysis:

• Strengths: Strong brand in endoscopy, global footprint, large shifting into the urology market.
• Weaknesses: Recent regulatory/quality issues (import alerts) risk reputation; heavy transition from legacy business.
• Opportunities: Growth in urology devices (including PCNL systems), single-use technology, and emerging markets.
• Threats: Regulatory scrutiny (especially from the FDA, quality system issues), competition from other med-tech firms, and economic headwinds.

Recent News & Updates

Press Releases / Industry Recognitions / Awards:

• September 2025: Distribution partnership with MacroLux Medical for single-use urology devices.  
• December 2024: Selected for inclusion in the Dow Jones Sustainability World Index for the fourth consecutive year.  
• Regulatory/Executive News: Allegation and subsequent removal of CEO in 2024 following illegal drug purchase charges; share price impact. 

Key Companies and Their contributions and offerings

• Karl Storz SE & Co. KG- It provided the IMAGE1 S suite, which offers full high-definition (FULL HD) visualization for surgical settings, during complex PCNL procedures.
• Cook Medical LLC- In March 2025, it facilitated Quanta System's Magneto technology on high-powered holmium laser systems.
• Richard Wolf GmbH- It offers a range of PCNL from standard-sized equipment to more minimally invasive options.

Top Companies in the Market

• Electro Medical Systems SA
• Terumo Corporation
• Coloplast A/S
• B. Braun Melsungen AG
• Zimmer Biomet Holdings, Inc.
• Teleflex Incorporated
• Dornier MedTech GmbH
• Merit Medical Systems, Inc.
• Attikouris Enterprises Ltd.
• Advin Urology
• Guangzhou Potent Optotronic Technology Co., Ltd.
• Surgimedik
• Allengers Medical Systems Ltd.
• Rocamed SAM
• Well Lead Medical Co., Ltd.

Recent Developments in the Percutaneous Nephrolithotomy (PCNL) System Market

• In October 2025, Hamad Medical Corporation (HMC) introduced the latest global system for kidney and ureter stone fragmentation, using extracorporeal shock wave lithotripsy technology at the Urology Department of the Ambulatory Care Center (ACC).
• In September 2025, Mendaera, Inc., a healthcare technology company, unveiled the world’s first procedures performed with the Focalist handheld robotic system.

Segments Covered in the Report

By Product/System Component

• Nephroscopes & Endoscopes
• Rigid nephroscopes
• Semi-rigid/flexible nephroscopes
• Lithotripsy Generators & Probes
• Holmium laser probes
• Ultrasonic lithotriptors
• Pneumatic/ballistic devices
• Access Sheaths, Dilators & Tract Kits
• Amplatz sheaths, balloon dilators, single-shot dilators
• PCNL Procedure Kits
• Guidewires & Access Needles
• Nephrostomy Catheters & Tubing
• Visualization & Imaging
• Ancillaries/Consumables
• Navigation/Software/Integrated Systems

By Procedure Type/Approach

• Standard (Conventional) PCNL
• Mini-PCNL/Miniaturized PCNL
• Ultra-mini/Micro-PCNL
• Supine PCNL vs Prone PCNL
• Tubeless PCNL/Day-case PCNL protocols
• Staged/Combined procedures

By Device Type 

• Reusable Rigid/Video Nephroscopes
• Single-use/Disposable Scopes & Sheaths
• Disposable Access Kits/Dilator Sets
• Reusable Ancillary Instruments

By End-User/Facility Type

• Hospitals (tertiary & general hospitals)
• Urology ORs, high-volume stone centers
• Ambulatory Surgical Centers (ASCs)/Day-case units)
• Specialty Urology Clinics/Stone Centers
• Academic & Research Centers

 By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
  • Germany
  • Italy
  • France
  • Netherlands
  • Spain
  • Portugal
  • Belgium
  • Ireland
  • UK
  • Iceland
  • Switzerland
  • Poland
  • Rest of Western Europe
• Eastern Europe 
  • Austria
  • Russia & Belarus
  • Türkiye
  • Albania
  • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  • GCC Countries
  • Saudi Arabia
  • United Arab Emirates (UAE)
  • Qatar
  • Kuwait
  • Oman
  • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA